The vaccine from Pfizer/BioNTech neutralizes the omicron variant after three doses, while the efficiency is lower after two doses, Report informs citing TASS that the company said in a statement.
"Preliminary evidence suggests that the third dose elicits a similar level of neutralizing antibodies to the omicron strain as it did after two doses against the other variants that occurred before it," the companies said.
At the same time, the study showed that after two doses, the efficiency is significantly lower. "This indicates that two doses of BNT162b2 do not provide sufficient protection against omicron strain contamination," the press release added.